ORPHA:280917
Idiopathic posterior uveitis
Publications
189
65.3th percentile
Trials
0
Interventional, condition-specific
Researchers
939
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
posterior uveitis is a rare, potentially sight-threatening, ocular disease, not attributed to any specific ocular or systemic cause, characterized by focal, multifocal or diffuse non-infectious inflammation in the posterior uvea (i.e. choroiditis, chorioretinitis, retinitis and neuroretinitis). Visual morbidity due to complications (including cystoid macular edema and choroidal neovascularization) has been reported.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017257
- UMLS:C4751435
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
189 matched papers (93 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 227 for broader category uveitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
189
189 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
189 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
93 in the last 10 years · high confidence · 65.3th percentile (publications denominator)
Phrase hits: 189 · MeSH hits: 0
Who's working on it?
939
Distinct author names in 189 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Nussenblatt RB8 papers · 2017
Laboratory of Immunology, National Institutes of Health, Bethesda, MD 20892-1858, USA. DrBob@intra.nei.nih.gov
Papers in Europe PMC - 02Sen HN8 papers · 2023
National Eye Institute, National Institutes of Health, Bethesda, MD. Electronic address: senh@nei.nih.gov.
Papers in Europe PMC - 03Mahajan VB7 papers · 2021
Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA
Papers in Europe PMC - 04Kubicka-Trzaska A5 papers · 2004
Katedra i Klinika Okulistyki Collegium Medicum UJ ul. Kopernika 38 31-501 Kraków.
Papers in Europe PMC - 05Yeh S5 papers · 2011
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, 10N-112, 10 Center Drive, Bethesda, MD 20892, USA.
Papers in Europe PMC - 06Zhang X5 papers · 2024
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China. xzhang08@tmu.edu.cn.
Papers in Europe PMC - 07Agrawal R4 papers · 2025
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Department of Medical Retina, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom; Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore. Electronic address: rupesh_agrawal@ttsh.com.sg.
Papers in Europe PMC - 08de Boer JH4 papers · 2023
Ophthalmo-Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Papers in Europe PMC - 09Folk JC4 papers · 2021
Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA
Papers in Europe PMC - 10Forrester JV4 papers · 2013Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial. 227 trials are registered for uveitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
227 interventional trials matched uveitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: uveitis
227
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06390436·NOT YET RECRUITING·Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
Conditions: Uveitis · Chronic Disease·Matched via name phrase
- NCT05105347·NOT YET RECRUITING·Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis
Conditions: Uveitis·Matched via name phrase
- NCT06258915·NOT YET RECRUITING·Treatment FOr Corticosteroid Dependent UveitiS
Conditions: Non Infectious Uveitis·Matched via name phrase
- NCT05984758·NOT YET RECRUITING·Imaging Based Uveitis Screening for Children With Juvenile Idiopathic Arthritis
Conditions: Uveitis, Anterior · Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT05928754·NOT YET RECRUITING·Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS
Conditions: Non-infectious Uveitis·Matched via name phrase
- NCT07513623·NOT YET RECRUITING·Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II
Conditions: Cytomegalovirus (CMV) · Anterior Uveitis · Infectious Uveitis · CMV Infection·Matched via name phrase
- NCT07285070·RECRUITING·Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
Conditions: Non-infectious Anterior Uveitis·Matched via name phrase
- NCT07427628·NOT YET RECRUITING·A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
Conditions: Non Infectious Uveitis·Matched via name phrase
- NCT05651880·NOT YET RECRUITING·Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
Conditions: Active Non-anterior Non-infectious Uveitis·Matched via name phrase
- NCT02706704·RECRUITING·Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
Conditions: Uveitis · Non-Infectious Uveitis·Matched via name phrase
- NCT07136805·NOT YET RECRUITING·A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Conditions: Non-infectious Anterior Uveitis·Matched via name phrase
- NCT07552012·RECRUITING·A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
Conditions: Active Non-anterior, Non-infectious Uveitis·Matched via name phrase
- NCT06539481·RECRUITING·Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
Conditions: Non-infectious Uveitis Affecting the Posterior Segment of the Eye·Matched via name phrase
- NCT07547995·RECRUITING·A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.
Conditions: Uveitis·Matched via name phrase
- NCT07145008·RECRUITING·Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
Conditions: Macular Edema (ME) · Non Infectious Uveitis·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT01440218·ENROLLING BY INVITATION·Idiopathic Diseases of Man
Conditions: Rare Disease · Idiopathic Disease·Matched via recall expansion
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Idiopathic posterior uveitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Idiopathic posterior uveitis" OR "idiopathic disease"
Recall-expansion terms: idiopathic disease
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"uveitis"
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:58:55.960Z
